Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018
Dr. Burris considers the results from the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score breast cancer patients
Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial
Dr. Burris considers the implications of the PERSEPHONE trial in early HER2+ breast cancer presented at the 2018 ASCO Annual Meeting
Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018
Dr. Denduluri elaborates on the results of the SANDPIPER study, specifically, whether adding taselisib to fulvestrant in ER+, PIK3CA-mutant breast cancer patients improved outcomes
Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting
Dr. Denduluri puts the PERSEPHONE trial into context with the Short-HER trial from ASCO 2017 and considers the standard of care of 12 months of trastuzumab in the early breast cancer setting
Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer
Dr. Denduluri considers whether the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines
Dr. Denduluri shares changes that have been recently incorporated into breast cancer guidelines
Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors
Dr. Denduluri discusses how to differentiate CDK4/6 inhibitors and whether they be used interchangeably
Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018
Dr. Denduluri elaborates on the implications of the TAILORx study presented at the 2018 ASCO Annual Meeting
Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018
Dr. Denduluri offers opinion on whether taselisib might one day become a standard of care based on the outcomes of the SANDPIPER study
Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Dr. Denduluri elaborates on the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing
Dr. Denduluri offers opinion on the practice-changing results of the TAILORx study presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER
Dr. Gralow considers whether taselisib will become a standard of care one day because of the outcomes of the SANDPIPER study presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018
Dr. Gralow considers the SANDPIPER study presented at the 2018 ASCO Annual Meeting and whether adding taselisib to fulvestrant in ER+, PIK3CA-mutant breast cancer patients improved outcomes
Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study
Dr. Gralow shares her thoughts on the practice-changing TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients
Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018
Dr. Gralow on whether the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients tells us endocrine therapy alone is similar in efficacy to chemoendocrine therapy
Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study
Dr. Gralow on whether the reduction of cardiac events in the PERSEPHONE study comparing 6 months versus 12 months of trastuzumab therapy in early breast cancer is compelling data
Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting
Dr. Gralow puts the PERSEPHONE trial into context with the ShortHER trial from the 2017 ASCO Annual Meeting as well as the standard of care of 12 months of trastuzumab in the early breast cancer setting
Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer
Dr. Gralow regarding the results of the PERSEPHONE trial in early HER2+ breast cancer presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study
Dr. Gralow regarding the improvement in PFS fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors
Dr. Gralow explains how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably
Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, discusses the biggest takeaway regarding breast cancer, in particular triple negative breast cancer, here at ASCO 2018
Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on if the results of the TAILORx study are practice changing
Douglas W. Blayney, MD, discusses the implications of the TAILORx study
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, discusses the TAILORx study and if endocrine therapy alone is similar in efficacy to chemotherapy + endocrine therapy
Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably
Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably
Dr. Tolaney explains how to differentiate CDK4/6 inhibitors and considers whether they can be used interchangeably
Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study
Dr. Tolaney shares details from the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study
Dr. Tolaney on if the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemotherapy + endocrine therapy
Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study
Dr. Tolaney on how significant the improvement in PFS fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”
Dr. Tolaney on whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients are “practice changing”
Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?
Sharon Karlsberg, Principal, Oncology, ZS Associates, considers the future of CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.
How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?
Sharon Karlsberg, Principal, Oncology, ZS Associates, considers how manufacturers can help institutions prepare for CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.
How Can a CAR-T Center Get Established and Effectively Treat Patients?
Sharon Karlsberg, Principal, Oncology, ZS Associates, discusses how a CAR-T center becomes established and effectively treats patients with Michael R. Bishop, MD, Professor of Medicine, Director, Hematopoietic Stem Cell Transplantation Program, University of Chicago.
Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC
Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients likely to benefit from immunotherapy
Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy
Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, and pembrolizumab
Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018
Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the outcomes change how we treat post-EGFR patients
Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC
Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell lung cancer (NSCLC)
Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC
Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)
Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC
Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable
Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC
Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer (NSCLC) patients likely to benefit from immunotherapy
Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab
Dr. Levy offers opinion on continuing pemextrexed maintenance after successful treatment of a non-small cell lung cancer (NSCLC) patient with carboplatin, pemetrexed and pembrolizumab
Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC
Dr. Levy shares key takeaways from the Impower150 study in non-small cell lung cancer (NSCLC) and whether the outcomes change how we treat post-EGFR patients
Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy
Dr. Levy elaborates on some of the current treatment options for non-small cell lung cancer (NSCLC) patients who progress on 1st line combination immunotherapy and chemotherapy
Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC
Dr. Levy considers how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell lung cancer (NSCLC)
Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189
Dr. Levy shares thoughts on the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)
Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC
Dr. Levy elaborates on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable
Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care
Malik Kaman, Associate Principal, Oncology, ZS Associates, sits down with Lee S. Schwartzberg, MD, Executive Director, West Cancer Center, Chief, Professor of Medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, to discuss novel endpoints and the future of cancer care.
Novel Endpoints in Cancer Care: What Lies Ahead
Malik Kaman, Associate Principal, Oncology, ZS Associates, sits down with Lee S. Schwartzberg, MD, Executive Director, West Cancer Center, Chief, Professor of Medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, to discuss what lies ahead for novel endpoints in cancer care.
Oncology Clinical Trials: Why We're Searching for Emerging Endpoints
Malik Kaman, Associate Principal, Oncology, ZS Associates, sits down with Lee S. Schwartzberg, MD, Executive Director, West Cancer Center, Chief, Professor of Medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, to discuss oncology clinical trials.
Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients
Dr. West elaborates on the role of Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients
Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab
Dr. West explains the role of maintenance therapy following successful treatment of a NSCLC patient with carboplatin, pemetrexed and pembrolizimab
NGS and Cancer: Combatting the Hazards of Misinformation
Jon Roffman, Managing Principal, ZS Associates, discusses how we can combat the hazards of misinformation related to NGS and cancer with Debra Patt, MD, MPH, MBA, Vice President, Texas Oncology.
Will NGS-Based Cancer Tests Become Routine?
Jon Roffman, Managing Principal, ZS Associates, discusses whether NGS-based cancer tests will become routine with Debra Patt, MD, MPH, MBA, Vice President, Texas Oncology.
Next-Gen Sequencing is Transforming Oncology Practices
Jon Roffman, Managing Principal, ZS Associates, discusses how next-generation sequencing is transforming oncology practices with Debra Patt, MD, MPH, MBA, Vice President, Texas Oncology.
Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC
Dr. West elaborates on the IMpower150 study in NSCLC and whether the outcomes impact treatment of post-EGFR patients
Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy
Dr. West outlines the current treatment options for NSCLC patients who progress on 1st line immunotherapy and chemotherapy combinations
Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC
Dr. West elaborates on the combination of chemotherapy and immunotherapy in the treatment of 1st line NSCLC
Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC
Dr. West offers opinion on whether NSCLC patients should be tested for PD-L1 expression and what level(s) of PD-L1 expression are actionable
Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC
Dr. Burris summarizes the evidence for the use of predictive biomarkers in non-small cell lung cancer (NSCLC)
Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design
Dr. Burris elaborates on some of the new and exciting concepts in clinical trial design
Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting
Dr. Burris discusses his goals for the 2019 ASCO Annual Meeting
Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC
Dr. Figlin offers opinion on whether the convenience of oral TKIs influences treatment decisions in advanced renal cell cancer patients.
Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC
Dr. Figlin regarding the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Robert A. Figlin, MD, provides perspective on I-O failures
Dr. Figlin considers the best course of action if a newly diagnosed advanced renal cell carcinoma (RCC) patient receives nivolumab & ipilimumab but continues to progress.
Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy
Dr. Figlin on deciding which metastatic RCC patients should get a TKI as first line therapy
Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients
Dr. Figlin on how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients
Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer
Dr. Stadler considers whether it is beneficial to add docetaxel to 1st line long-term hormone therapy in patients with prostate cancer
Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms
Dr. Stadler tells us how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms
Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer
Dr. Stadler elaborates on the outcomes of the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer
Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma
Dr. Stadler comments on whether TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which seem to have a significant impact in 1st line RCC
Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure
Dr. Stadler elaborates on how an advanced renal cell carcinoma (RCC) patient should be treating in the 2nd line setting following I-O therapy failure
Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy
Dr. Stadler on deciding which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy
David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC
Dr. Quinn discusses the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options
David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment
Dr. Quinn on whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced renal cell carcinoma (RCC) patients
David I. Quinn, MD, comments on 2nd line therapy options following I-O failure
Dr. Quinn considers how an advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line setting following I-O failure
David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting
Dr. Quinn discusses Keynote 427 presented at the 2018 ASCO Annual Meeting
David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018
Dr. Quinn provides opinion on the most interesting renal cell carcinoma (RCC) data being presented at the 2018 ASCO Annual Meeting
Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms
Dr. Aragon-Ching elaborates on how checkpoint inhibitors figure into the treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients
Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure
Dr. Aragon-Ching elaborates on how an advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line setting following I-O therapy failure
Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer
Dr. Aragon-Ching on whether the response rates for erdafitinib in metastatic bladder cancer look promising and potentially practice-changing
Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer
Dr. Aragon-Ching considers whether there are reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should receive neoadjuvant therapy
Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer
Dr. Aragon-Ching elaborates on how new guidelines have changed the treatment of advanced metastatic bladder cancer
Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials
Dr. Aragon-Ching tells us how the outcomes of the PROSPER and SPARTAN trials in non-metastatic castrate-resistant prostate cancer are impacting standard of care
Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018
Dr. Jahanzeb on whether the outcomes of Keynote 42 presented at the 2018 ASCO Annual Meeting will impact his patient selection
Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy
Dr. Jahanzeb offers opinion on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin, pemetrexed and pembrolizumab
Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection
Dr. Jahanzeb considers whether the results of Keynote 189 impact PDL-1 expression and patient selection
Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting
Dr. Wang offers opinion on exciting data coming out of the 2018 ASCO Annual Meeting
Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients
Dr. Wang discusses whether there is a role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients
Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML
Dr. Wang discusses some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior TKI therapy
Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting
Dr. Wang elaborates on what we've learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients
Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML
Dr. Wang regarding the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with FLT3-ITD acute myeloid leukemia (AML)
Eunice Wang, MD, on next-generation sequencing and treatment selection in AML
Dr. Wang considers the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML)
Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing
Dr. Steinberg provides opinion on whether FGFR inhibitors are a promising drug class in metastatic bladder cancer and have potential to be practice-changing
Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database
Dr. Green discusses how Flatiron's clinico-genomic database may help shed light on the cost-effectiveness of next-generation sequencing
Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database
Dr. Green tells us why physicians should be excited about Flatiron’s clinico-genomic database and how it may be used to direct treatments
Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting
Dr. Green considers what people will be talking about the most from the 2018 ASCO Annual Meeting
Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC
Dr. Abou-Alfa offers opinion on some of the shortcomings of RECIST in measuring efficacy in hepatocellular carcinoma (HCC) patients
Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018
Dr. Abou-Alfa tell us about the outcomes of the CELESTIAL trial and how the results should be applied to everyday practices
Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs
Dr. Abou-Alfa offers opinion on how immunotherapies should be combined with TKIs at this time
Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC
Dr. Abou-Alfa outlines the latest thinking regarding systemic therapy for advanced hepatocellular carcinoma (HCC) at the 2018 ASCO Annual Meeting
Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting
Dr. Mallick discusses some of the advances in the treatment of colorectal cancer coming out of the 2018 ASCO Annual Meeting
Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms
Dr. Mallick explains how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms
Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms
Dr. Mallick tells us how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC
Dr. Mallick comments on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Mallick elaborates on the patient type and setting where vemurafenib has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment
Dr. Mallick explains how the stage of colorectal cancer (CRC) and the mismatch repair status impact treatment algorithms
Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer
Dr. Mallick shares her thoughts on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer”
John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”
Dr. Leighton offers opinion on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer” coming out of the 2018 ASCO Annual Meeting
John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer
Dr. Leighton shares the results of the PREOPANC-1 study at the 2018 ASCO Annual Meeting and if, as a result, resectable pancreatic cancer patients should recieve preoperative chemotherapy before surgery
John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018
Dr. Leighton elaborates on whether mFOLFIRINOX should be used in the adjuvant setting for patients with resected pancreatic cancer according to the PA.6 clinical study presented at the 2018 ASCO Annual Meeting
John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms
Dr. Leighton discusses whether tumor sidedness impacts colorectal cancer treatment algorithms
John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC
Dr. Leighton elaborates on the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC
Dr. Hochster provides perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated single agent oxaliplatin after surgery
Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018
Dr. Hochster regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction in metastatic colorectal cancer patients
Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC
Dr. Hochster discusses the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients
Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC
Dr. Lara elaborates on whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which TKIs seem to be the most successful in 1st line renal cell carcinoma (RCC)
Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions
Dr. Lara discusses whether the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma (RCC) treatment
Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment
Dr. Lara discusses the trade-offs between safety and efficacy when considering 1st line renal cell carcinoma (RCC) treatment options
Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure
Dr. Lara elaborates on how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line following I-O failure
Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI
Dr. Lara elaborates on how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy
Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms
Dr. Lara considers how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients
Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer
Dr. Higano comments on how immunotherapy is currently being integrated into castrate resistant prostate cancer treatment algorithms
Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018
Dr. Higano tells us how the outcomes from the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer are impacting the standard of care
Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab
Dr. Santos offers opinion on the benefits of using docetaxel plus ramucirumab verus docetaxel alone in 2nd line non-small cell lung cancer (NSCLC)
Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy
Dr. Santos offers opinion on continued pemetrexed maintenance following successful treatment of a patient with combination carboplatin, pemetrexed and pembrolizumab
Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC
Dr. Santos considers whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his view of PDL-1 expression and patient selection
Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018
Dr. Santos elaborates on the exciting developments coming out of the 2018 ASCO Annual Meeting
Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018
Dr. Rini on the impact of the CARMENA study presented at the 2018 ASCO Annual Meeting on the treatment of intermediate and poor risk metastatic renal cell carcinoma (mRCC) patients
Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs
Dr. Rini considers whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced renal cell carcinoma (RCC) patients
Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC
Dr. Rini considers the trade-offs between safety and efficacy when discussing 1st line renal cell carcinoma (RCC) treatment options
Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure
Dr. Rini provides opinion on treatment for renal cell carcinoma (RCC) patients following I-O failure
Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy
Dr. Rini elaborates on how he decides which metastatic renal cell carcinoma (RCC) patients should receive a TKI as 1st line therapy
Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC
Dr. Rini explains how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients
James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer
Dr. Posey on whether the LAPACT study adding nab-paclitaxel to gemcitabine improve efficacy for locally advanced pancreatic cancer patients?
James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer
Dr. Posey explains how new immunotherapy agents have impacted the outcomes in pancreatic cancer
James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma
Dr. Posey considers the key unmet medical needs in pancreatic ductal adenocarcinoma today
James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer
Dr. Posey comments on the results of the PREOPANC-1 study from the 2018 ASCO Annual Meeting and considers the role of preoperative chemotherapy for resectable pancreatic cancer patients
James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018
Dr. Posey considers whether mFOLFIRINOX should be used in the adjuvant setting for patients with resected pancreatic cancer according to the PA.6 clinical study presented at the 2018 ASCO Annual Meeting
Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments
Dr. Abraham offers opinion on how we might demonstrate the value of cancer care in today's oncology landscape
Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement
Dr. Abraham provides perspective on biosimilar pricing and reimbursement
Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval
Dr. Abraham tells us about those biosimilars that have been approved and those that are close to approval
Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars
Dr. Abraham describes the potential hurdles that might prevent the adoption of biosimilars by oncologists
Ivo Abraham, PhD, RN, explains the key features of a biosimilar
Dr. Abraham discusses some of the key characteristics of a biosimilar
Randall A. Oyer, MD, considers the work being done to address disparities in healthcare
Dr. Oyer elaborates on how ACCC is contributing to the work being done to address disparities in healthcare, including the implementation of the Optimal Care Coordination Model (OCCM)
Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute
Dr. Oyer on immunotherapy data coming out of the 2018 ASCO Annual Meeting and the purpose of the ACCC Immuno-Oncology Institute
Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018
Dr. Oyer elaborates on how ACCC is utilizing the data on genetics presented at the 2018 ASCO Annual Meeting
Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the benefits of using Cyramza (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line Non Small Cell Lung Cancer (NSCLC)
Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses drug sequencing as a result of Keynote 189 and 42 results
Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, on if patient selection will change as a result of Keynote 42
Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, on whether to continue pemetrexed maintenance after successful treatment of the patient with carboplatin / pemetrexed / pembrolizumab
Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, shares what's exciting here at ASCO 2018
Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection
Dr. Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, on whether Keynote 189 impacted view of PDL-1 expression and patient selection
Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, discusses the use of Watson in the VA Precision Oncology Program
Lisa Rometty shares some of the recent accomplishments of IBM's Watson
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, describes some of the recent accomplishments IBM has made in establishing Watson as a point of care decision-making tool
Lisa Rometty elaborates on Watson's role in clinical trial matching
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, tells us how Watson is helping to identify and match cancer patients to clinical trials at the point of care
Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, discusses how data from Watson can impact real-world evidence and ultimately clinical decision making
Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how augmented intelligence is helping oncologists make everyday decisions when treating cancer patients
Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms
Dr. Beer on how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms
Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care
Dr. Beer on how the outcomes in the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer are impacting standard of care
Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer
Dr. Beer discusses the latest trends in the multimodality treatment of prostate cancer
Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer
Dr. Beer on how to avoid under diagnosing and over diagnosing prostate cancer
Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018
Dr. Beer discusses the central themes regarding prostate cancer here at ASCO 2018
Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting
Dr. Levis offers his opinion on the most exciting clinical trial data coming out of the 2018 ASCO Annual Meeting
Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML
Dr. Levis tells us about the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior FLT3 TKI therapy
Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients
Dr. Levis shares what new information we've learned about gilteritinib in FLT3 mutated acute myeloid leukemia (AML)
Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML
Dr. Levis elaborates on the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid acute myeloid leukemia (AML)
Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations
Dr. Levis comments on the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations
Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML
Dr. Levis elaborates on the impact of next-generation sequencing in treatment selection in acute myeloid leukemia (AML)
Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis
Dr. Vogelzang provides opinion on whether imaging could be a cost-effective, long-term solution for diagnosis of prostate cancer
Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer
Dr. Vogelzang shares how MRI has improved the diagnosis of prostate cancer
Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer
Dr. Vogelzang explains on how to avoid under-diagnosing & over-diagnosing prostate cancer
Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"
Dr. Goldberg provides opinion on the headline, "Immunotherapy Now Standard for Some Patients With Colorectal Cancer" coming out of the 2018 ASCO Annual Meeting
Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients
Dr. Goldberg tells us about the outcomes the PRODIGY7 study in metastatic colorectal cancer (mCRC) patients using heated single agent oxaliplatin after surgery
Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405
Dr. Goldberg discusses how the FIRE-3 study presented at the 2018 ASCO Annual Meeting reinforces the CALGB 80405 data in 1st line metastatic colorectal cancer (CRC) patients
Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer
Dr. Goldberg elaborates on preoperative chemotherapy in pancreatic cancer and whether the PREOPANC-1 study presented at the 2018 ASCO Annual Meeting has influenced the path of treatment
Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer
Dr. Goldberg considers whether mFOLFIRINOX should be used in the adjuvant setting for patients with resected pancreatic cancer as a result of the PA.6 clinical study
Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute
Dr. Crews discusses a few of the key initiatives in 2018 for the ACCC Immuno-Oncology Institute
Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy
Dr. Schiller concerning Keynote trials presented at the 2018 Annual Meeting and whether they will impact her choice of therapy for squamous or non-squamous lung cancer patients
Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker
Dr. Schiller discusses whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those patients likely to benefit from immunotherapy
Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens
Dr. Schiller elaborates on what her drug sequencing regimen looks like as a result of Keynote 189 and Keynote 42 data presented at the 2018 ASCO Annual Meeting?
Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting
Dr. Schiller elaborates on Keynote 42 data and how it might impact patient selection
Joan Schiller, MD, considers the continuation of pemetrexed maintenance
Dr. Schiller provides opinion on whether she would continue pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection
Dr. Schiller discusses Keynote 189 presented at the 2018 ASCO Annual Meeting and whether the data impacts her view of PDL-1 expression and patient selection
Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute
Dr. Crews describes the mission of the ACCC Immuno-Oncology Institute
Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Dr. Benson, Professor of Medicine, Northwestern University, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC
Dr. Benson, Professor of Medicine, Northwestern University, the role of I-O and immunotherapy combinations when treating colorectal cancer
Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study
Dr. Benson, Professor of Medicine, Northwestern University, tells us about the outcomes of the ECOG-ACRIN study in advanced pancreatic neuroendocrine tumors
Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers
Dr. Crews elaborates on how community oncology is interpreting and incorporating biomarkers into their immuno-oncology therapeutic choices
Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Dr. Biran shares her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients
Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma
Dr. Biran offers opinion on whether bortezomib, pomalidomide, and low-dose dexamethasone (VPd) is effective in relapsed multiple myeloma patients.
Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study
Dr. Biran tells us about the logistics involved in delivering CAR-T in the BB2121 study in multiple myeloma patients
Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma
Dr. Biran considers the impact of the BB2121 study in multiple myeloma patients and how the results compare to the standard of care
Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018
Dr. Biran offers her opinion on the most exciting clinical data presented at the 2018 ASCO Annual Meeting
David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses drug sequencing in lung cancer as a result of Keynote 189 and 42 results
David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, on what will change about patient selection as a result of Keynote 42
David R. Gandara, MD, on continuing pemextrexed maintenance
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, on continuing pemextrexed maintenance after successful treatment of the patient with carboplatin / pemetrexed / pembrolizumab
David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center on whether Keynote 189 impact view of PDL-1 expression and patient selection
David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, shares the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line NSCLC
David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018
Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses exciting new developments in lung cancer here at ASCO 2018
Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens
Dr. Jahanzeb shares what he might do in terms of sequencing therapies as a result of Keynote 189 and Keynote 42 presented at the 2018 ASCO Annual Meeting
David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy
Dr. Quinn considers which metastatic RCC patients should receive a TKI as first-line therapy
Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer
Dr. Steinberg on whether FGFR inhibitors in metastatic bladder cancer have the potential to be practice changing
Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC
Dr. Higano discusses interesting new data being presented here at ASCO in metastatic castrate-resistant prostate cancer (CRPC)
Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer
Dr. Higano discusses how MRI has improved the diagnosis of prostate cancer
Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer
Dr. Higano on imaging as a cost-effective, long-term solution for diagnosis of prostate cancer
Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients
Dr. Benson, Professor of Medicine, Northwestern University, discusses what molecular markers are most important to test for when treating colorectal cancer patients
